The European Medicines Agency (EMA) announced on Friday 30 July that it had approved “a scale-up of the active substance production process” of the Covid-19 vaccine Spikevax, developed by the company Moderna.
This “scale-up”—which does not require European Commission approval—involves two US vaccine manufacturing sites: ModernaTX, Inc. in Norwood, Massachusetts, and Lonza Biologics, Inc. in Portsmouth, New Hampshire.
The EMA’s recommendation is intended to confirm that both...